Acetamides

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Tuesday, August 3, 2021
Natural sciences, Chemistry, Branches of biology, Neuraminidase inhibitors, Carbohydrate chemistry, Acetamides, Guanidines, BioCryst Pharmaceuticals, Peramivir, Neuraminidase, Viral neuraminidase, Enzyme

The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Each stock option has a 10-year term and is subject to the terms and conditions of BioCrysts Inducement Equity Incentive Plan and a stock option agreement covering the grant.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

Global Coalition for Adaptive Research Announces the Discontinued Evaluation of Apremilast in REMAP-COVID

Retrieved on: 
Monday, July 12, 2021
Health, Infectious diseases, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Phthalimides, Life sciences, Acetamides, Amgen, Apremilast, Health sciences, Virotherapy, Medicine, Immunotherapy

Global Coalition for Adaptive Research, the U.S.

Key Points: 
  • Global Coalition for Adaptive Research, the U.S.
  • Sponsor of REMAP-COVID, announced that Amgens apremilast (Otezla) has ended evaluation in the REMAP-COVID study.
  • Apremilast was evaluated within one of two domains of the study evaluating immune modulation.
  • This vital research is being conducted in collaboration with Berry Consultants, leaders in statistical design for adaptive platform trials, and is being supported by governments and non-profits worldwide.

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Retrieved on: 
Wednesday, June 9, 2021
Chemical compounds, Psychoactive drugs, Branches of biology, Hypnotics, GABAA receptor positive allosteric modulators, Pyridines, Orexin antagonist, G protein-coupled receptors, Acetamides, Lemborexant, Orexin receptor, Zolpidem

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome

Retrieved on: 
Thursday, June 3, 2021
Drugs, Organ systems, Health, Chloroarenes, CYP17A1 inhibitors, Acetamides, Dioxolanes, Adrenal gland disorders, Cushing's syndrome, Steroidogenesis inhibitor, Ketoconazole, Levoketoconazole

11,020,393 entitled, Methods of Treating Disease with Levoketoconazole which covers a method of treating Cushings syndrome patients with RECORLEV (levoketoconazole) who also take metformin for Type 2 diabetes.

Key Points: 
  • 11,020,393 entitled, Methods of Treating Disease with Levoketoconazole which covers a method of treating Cushings syndrome patients with RECORLEV (levoketoconazole) who also take metformin for Type 2 diabetes.
  • 9,918,984, covers methods of treating Cushings syndrome with levoketoconazole and will expire on January 10, 2026.
  • RECORLEV is an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the U.S. Food and Drug Administration for the treatment of endogenous Cushings syndrome.
  • RECORLEV has received orphan drug designation from the FDA and theEuropean Medicines Agencyfor the treatment of endogenous Cushing's syndrome.

Promescent Debuts Medical Advisory Board's 'Ask-a-Doctor' Portal

Retrieved on: 
Wednesday, May 26, 2021
Local anesthetics, Acetamides, Lidocaine, Advisory board, Drugs, Medical specialties, Clinical medicine

Introduced in early February 2021, Promescent's Medical Advisory Board provides additional perspectives and years of board-certified expertise to customers, while advising product development strategy and leading medical outreach initiatives.

Key Points: 
  • Introduced in early February 2021, Promescent's Medical Advisory Board provides additional perspectives and years of board-certified expertise to customers, while advising product development strategy and leading medical outreach initiatives.
  • Promescent's Medical Advisory Board will be available through the company's "Ask a Doctor" submission form and corresponding column.
  • The Ask-a-Doctor Portal allows us to offer our customers the same informed opinions that we rely on," says Jeff Abraham, CEO of Promescent.
  • Absorption Pharmaceuticals is the maker of Promescent, a lidocaine spray made with careful consideration for the people who use it.

Global $2.09 Billion Chitosan Market Size, Trends & Growth to 2028 by Grade, Source, Application, and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Retail, Agriculture, Natural Resources, Food, Beverage, Biopesticides, Polysaccharides, Chemistry, Acetamides, Biomolecules, Chitosan, Elicitors, Branches of biology, Chitin, Physical sciences, Polysaccharide, Dietary supplement

b'The "Chitosan Market Size, Trends & Growth, By Grade, By Source, By Application, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global chitosan market size is expected to reach USD 2,093.5 Million in 2028, and register a CAGR of 12.9% during the forecast period.\nGrowing awareness regarding health benefits of chitosan and increasing prevalence of various diseases are key factors driving market revenue growth.

Key Points: 
  • b'The "Chitosan Market Size, Trends & Growth, By Grade, By Source, By Application, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global chitosan market size is expected to reach USD 2,093.5 Million in 2028, and register a CAGR of 12.9% during the forecast period.\nGrowing awareness regarding health benefits of chitosan and increasing prevalence of various diseases are key factors driving market revenue growth.
  • Increasing use of chitosan as one of the essential ingredients in dietary supplements.\nChitosan is polysaccharide chitin derivative sourced from crustacean shell waste such as from lobsters, shrimps, prawns, crabs, as well as white mushrooms.
  • In gastrointestinal (GI) tract, chitosan helps restrict lipid absorption, thus, it is highly preferred to be added in dietary supplements.
  • Chitosan has non-toxic properties which are extremely useful industrial activities such as water purification and other water treatment processes.

FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis

Retrieved on: 
Wednesday, May 5, 2021
Acetamides, Amgen, Apremilast, Phthalimides, Psoriasis, Organ systems, Medical specialties, Phosphodiesterase-4 inhibitor

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2021.\n"Otezla has been prescribed to hundreds of thousands of patients with moderate-to-severe plaque psoriasis.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2021.\n"Otezla has been prescribed to hundreds of thousands of patients with moderate-to-severe plaque psoriasis.
  • The study randomized 595 patients 1:1 to receive Otezla (n=297) 30 mg twice daily or placebo (n=298) for the first 16 weeks.
  • PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators.
  • Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506).

BioCryst to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 5, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, Neuraminidase, BioCryst Pharmaceuticals, XC2, Viral neuraminidase

b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.
  • ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m.
  • ET.
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Report First Quarter 2021 Financial Results on May 6

Retrieved on: 
Thursday, April 22, 2021
Neuraminidase inhibitors, Chemistry, Carbohydrate chemistry, Enzymes, Branches of biology, Acetamides, Guanidines, Peramivir, BioCryst Pharmaceuticals, Neuraminidase, XC2, Conference call

b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.\nThe live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2660434.
  • A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com .
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion

Retrieved on: 
Friday, April 9, 2021
Health sciences, Drugs, Pharmacology, Local anesthetics, Acetamides, Lidocaine, Topical medication

PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (Scilex), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, Sorrento), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido to make efficacy labeling change with clinical data.

Key Points: 
  • PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (Scilex), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, Sorrento), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido to make efficacy labeling change with clinical data.
  • ZTlido is the only lidocaine topical system that has been studied under the water stress conditions, and now has FDA label reflecting its use while showering, swimming and bathing.
  • The trial showed that the topical system may be used while showering and that this does not increase lidocaine plasma levels.
  • Scilex Holding Company, a majority-owned subsidiary of Sorrento, is a commercial-stage, non-opioid pain management company focused on the development and commercialization of topical and injectable therapies.